Does Medicare Cover Wegovy? The 2024 CMS Rule and the Cardiovascular Indication

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 14 sources cited

As of May 2026. Confirm directly with your plan. Coverage varies by Part D plan, region, and time. Always confirm with your specific plan administrator.

Key Takeaways

• Medicare Part D covers Wegovy only for the FDA-approved cardiovascular indication after the November 2024 CMS final rule. Weight loss alone remains excluded by Part D statute
• The cardiovascular indication, approved by the FDA in March 2024 based on the SELECT trial, applies to adults with established cardiovascular disease and BMI 27 or higher
• The CMS rule did not remove the weight-loss exclusion. It clarified how Part D plans can cover GLP-1 medications for non-weight-loss FDA-approved indications
• The 2025 Inflation Reduction Act $2,000 annual Part D out-of-pocket cap applies. Chronic Wegovy patients typically reach the cap within several fills
• The Novo Nordisk Wegovy Savings Card is not available to Medicare beneficiaries. The patient assistance program is the alternative

Direct answer

Medicare Part D covers Wegovy when prescribed for the FDA-approved cardiovascular indication, following the November 2024 CMS final rule. Coverage requires documented established cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary revascularization) and BMI 27 or higher. Medicare does not cover Wegovy for weight loss alone, regardless of BMI, because of the Part D statutory weight-loss exclusion. The 2025 $2,000 annual out-of-pocket cap applies for covered fills.

Table of contents

1. The November 2024 CMS rule: what it actually says
2. The SELECT trial and the FDA cardiovascular indication
3. Who qualifies: clinical criteria for the CV indication
4. The Part D weight-loss exclusion still in force
5. Part D plan PA criteria for Wegovy under the new rule
6. Cost-sharing under the 2025 $2,000 OOP cap
7. Medicare Advantage MA-PD coverage of Wegovy
8. The Novo Nordisk patient assistance program for Medicare patients
9. Low-Income Subsidy (Extra Help) and Wegovy
10. Part D appeals: the path when Wegovy is denied
11. The CBO projections and the policy debate around the weight-loss exclusion
12. When Medicare won't cover: alternatives including 503A compounded
13. Contrary view: the case for and against expanded coverage
14. Decision framework
15. FAQ
16. Sources

The November 2024 CMS rule: what it actually says

The Centers for Medicare and Medicaid Services published a final rule in November 2024 clarifying how Part D plans should handle GLP-1 medications that have both weight-loss and non-weight-loss FDA-approved indications. The rule addressed a gap created by the FDA's March 2024 approval of Wegovy for cardiovascular risk reduction.

The substance of the rule:

• Part D plans may cover GLP-1 medications when prescribed for an FDA-approved non-weight-loss indication, even when the medication is also approved for weight loss
• The prescribing clinician must indicate the medication is for the non-weight-loss indication (the cardiovascular indication, in Wegovy's case)
• The Part D weight-loss exclusion continues to apply when the prescription is for weight loss alone
• Part D plans have discretion on whether to include such medications on the formulary and what PA criteria to apply

The rule did not remove the Part D weight-loss exclusion. The exclusion is codified at Social Security Act Section 1860D-2(e)(2) and requires Congressional action to remove. The rule provides a pathway for Part D coverage of GLP-1 medications for non-weight-loss indications, which is what the FDA cardiovascular approval created for Wegovy.

The SELECT trial and the FDA cardiovascular indication

The SELECT trial (Lincoff et al., NEJM 2023) randomized 17,604 adults with overweight or obesity (BMI 27 or higher) and established cardiovascular disease to receive semaglutide 2.4 mg weekly or placebo. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Key SELECT findings:

• The primary outcome occurred in 6.5% of the semaglutide group vs 8.0% of the placebo group, a 20% relative risk reduction (hazard ratio 0.80, 95% CI 0.72 to 0.90, p<0.001)
• Mean weight loss in the semaglutide group was about 9.4% over the trial period
• Treatment effects on cardiovascular outcomes appeared independent of weight loss, suggesting direct cardiovascular benefit from semaglutide
• Safety profile was consistent with prior semaglutide trials, with no new signals

The FDA approved Wegovy for the cardiovascular indication in March 2024 based on SELECT. The labeled indication reads: "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight."

Who qualifies: clinical criteria for the CV indication

Beneficiaries who qualify for Part D coverage of Wegovy under the CMS rule must meet the FDA cardiovascular indication criteria. Most Part D plans require documentation of:

• Established cardiovascular disease, which includes:
  • Prior myocardial infarction
  • Prior ischemic stroke
  • Prior coronary revascularization (CABG, PCI)
  • Prior peripheral artery disease with revascularization or amputation
  • Documented obstructive coronary artery disease (e.g., 50% stenosis on angiography)
• BMI of 27 or higher
• Age 45 or older (the SELECT trial enrolled adults age 45+)
• Prescription written for the cardiovascular indication

The plan's PA form will ask the prescriber to attest to these criteria. Documentation in the chart supports the attestation.

The Part D weight-loss exclusion still in force

Section 1860D-2(e)(2)(A) of the Social Security Act excludes from Part D coverage "agents when used for anorexia, weight loss, or weight gain." This statutory exclusion has been in force since the Part D program began in 2006.

Beneficiaries with obesity but no established cardiovascular disease are not covered for Wegovy under Medicare. The patient may have BMI 35 with type 2 diabetes; if they do not have cardiovascular disease, Wegovy is not covered for weight loss under Part D. Ozempic may be covered for the T2D indication, but Wegovy at the obesity dose is not.

The exclusion is a frequent target of advocacy and legislation. The Treat and Reduce Obesity Act has been introduced repeatedly in Congress to remove the exclusion. As of May 2026, no enacted legislation has removed it.

Part D plan PA criteria for Wegovy under the new rule

Each Part D sponsor sets its own PA. The criteria converge:

• Documented established cardiovascular disease (with specific events listed)
• BMI of 27 or higher
• Age 45 or older typically
• Prescription written for the cardiovascular indication, not weight loss
• Sometimes a documented prior trial of cardiovascular risk-reduction therapy (statin, anti-platelet) with continued elevated risk

The PA is submitted by the prescriber. Decisions arrive within 72 hours standard, 24 hours expedited.

Cost-sharing under the 2025 $2,000 OOP cap

The Inflation Reduction Act changed Part D's structure. As of January 2025:

1. Deductible phase: pay full negotiated price up to the plan's annual deductible (maximum $590 in 2026)
2. Initial coverage phase: copay or coinsurance for each fill until OOP reaches $2,000
3. Catastrophic phase: $0 for the rest of the calendar year once OOP cap is reached

For Wegovy at retail prices near $1,350 per fill, beneficiaries typically reach the $2,000 OOP cap within a few fills. The remainder of the calendar year is $0.

The Medicare Prescription Payment Plan allows beneficiaries to spread the $2,000 OOP across the calendar year in monthly installments. This eliminates large upfront pharmacy costs early in the year.

Medicare Advantage MA-PD coverage of Wegovy

Medicare Advantage plans with Part D (MA-PD) follow the same federal Part D rules. Wegovy is covered for the cardiovascular indication, not for weight loss alone. Specific MA-PD plans set tier placement and may apply additional plan-level PA within the federal framework.

Major MA-PD sponsors that have added Wegovy for the CV indication include UnitedHealthcare, Humana, Aetna, Cigna, and various Blue plans. Tier placement varies. The $2,000 OOP cap applies across MA-PD plans.

The Novo Nordisk patient assistance program for Medicare patients

The Wegovy Savings Card is not available to Medicare beneficiaries due to the federal anti-kickback statute. The Novo Nordisk patient assistance program (PAP) is the alternative.

PAP eligibility as of 2026 typically requires:

• U.S. residency
• Income at or below roughly 400% of federal poverty level
• No prescription drug coverage, or coverage that does not pay for the medication, or significant cost burden
• Prescription from a U.S.-licensed clinician

Approved patients receive Wegovy at no cost through specific pharmacy partners. Reapplication required annually.

Low-Income Subsidy (Extra Help) and Wegovy

The Low-Income Subsidy (LIS), known as Extra Help, reduces Part D costs for income-qualified Medicare beneficiaries. As of 2026, full LIS recipients pay copays of approximately $4.50 for generics and $11.20 for brand-name drugs.

For Wegovy under the cardiovascular indication, LIS recipients pay the brand-name LIS copay per fill. This is a major cost reduction compared to standard cost-sharing.

Apply for LIS through Social Security. The expanded 2024 eligibility (up to 150% of federal poverty level) means more beneficiaries qualify than under the prior 135% threshold.

Part D appeals: the path when Wegovy is denied

If a Part D plan denies Wegovy coverage, the appeal path:

1. Coverage Determination: initial request, decision within 72 hours standard, 24 hours expedited
2. Redetermination: first-level appeal with the same plan, decision within 7 days standard, 72 hours expedited
3. Independent Review Entity (IRE): second-level appeal, decision within 7 days standard, 72 hours expedited
4. Administrative Law Judge (ALJ): third-level if amount in controversy is met
5. Medicare Appeals Council
6. Federal District Court

For Wegovy specifically, the appeal must demonstrate that the prescription is for the cardiovascular indication, not weight loss alone. The chart documentation of established cardiovascular disease is the linchpin.

The CBO projections and the policy debate around the weight-loss exclusion

The Congressional Budget Office has estimated that removing the Part D weight-loss exclusion would cost Medicare roughly $40 billion over a decade. The estimate reflects assumptions about uptake, drug pricing under future Medicare price negotiation, and offsetting savings from reduced obesity-related Medicare spending.

The policy debate continues. Proponents of removing the exclusion cite the documented cardiovascular and renal benefits of GLP-1 medications, the reclassification of obesity as a chronic disease by major medical bodies, and the Medicare-cost implications of obesity-related complications. Opponents cite the price tag, the precedent for covering lifestyle-adjacent drugs, and uncertainty about long-term real-world outcomes in Medicare populations.

Congressional action would be required to remove the exclusion. The CMS rule represents the maximum that the agency can do administratively to address the GLP-1 cardiovascular coverage question.

When Medicare won't cover: alternatives including 503A compounded

For Medicare beneficiaries who do not qualify under the cardiovascular indication, the alternatives:

• The Novo Nordisk patient assistance program for income-qualified patients
• Cash pricing (the Medicare Prescription Payment Plan does not apply to non-covered drugs)
• 503A compounded semaglutide via telehealth (cash-pay, not billable to Medicare)

503A compounded semaglutide is prepared by a state-licensed 503A pharmacy on an individual prescription basis. It is the same active molecule as Wegovy but is not FDA-approved and not equivalent to brand-name Wegovy. FormBlends works with state-licensed 503A pharmacies and licensed clinicians for clinically eligible patients.

For Medicare beneficiaries with established cardiovascular disease who do qualify under the CMS rule, the strong recommendation is to pursue Part D coverage first. The $2,000 OOP cap makes brand-name Wegovy through Medicare significantly more affordable than before.

Contrary view: the case for and against expanded coverage

The Part D weight-loss exclusion looks anachronistic in 2026. Obesity is widely recognized as a chronic disease. GLP-1 medications produce cardiovascular and renal benefits documented in trials beyond SELECT (FLOW for kidney outcomes, STEP-HFpEF for heart failure with preserved ejection fraction, others). Excluding these medications from Medicare for the weight-loss indication while covering them for cardiovascular indication creates a clinical inconsistency.

The defense rests on cost. Medicare drug spending is rising. Adding broad GLP-1 weight-loss coverage to Part D would expand spending materially. That cost gets paid through Medicare trust fund spending, beneficiary premiums, and federal general revenue. The opportunity cost includes other Medicare programs and other health priorities.

The November 2024 CMS rule threads the needle: it covers GLP-1 medications for documented non-weight-loss indications without removing the statutory weight-loss exclusion. Future Congressional action will determine whether the exclusion holds. Reasonable people on both sides.

Decision framework

If you have established cardiovascular disease and BMI 27+: ask your prescriber whether Wegovy is clinically appropriate. The CMS rule provides a coverage path. The PA documentation is the key. The $2,000 OOP cap limits annual exposure.

If you have obesity without cardiovascular disease: Medicare does not cover Wegovy. Pursue the patient assistance program or 503A compounded as cash-pay options.

If you are low-income: apply for Extra Help (LIS). The application is short and the savings are substantial.

If you have only Original Medicare: consider adding Part D or MA-PD at the next Open Enrollment.

If you are denied: work the Part D appeals process. The IRE stage is where most reversals happen when documentation is complete.

FAQ

Does Medicare cover Wegovy? Only for the cardiovascular indication after the November 2024 CMS rule.

What about weight loss? Not covered. Part D statutory weight-loss exclusion.

What qualifies for the CV indication? Established cardiovascular disease, BMI 27+, age 45+ typically, prescription for the CV indication.

Cost? $50 to $150 per fill until reaching the $2,000 annual OOP cap, then $0.

Manufacturer card? Not available to Medicare beneficiaries.

Extra Help? LIS recipients pay roughly $11.20 per brand fill.

How do I appeal a denial? Coverage Determination, Redetermination, IRE, ALJ, MAC, federal court.

Sources

1. Centers for Medicare and Medicaid Services. Final rule on Part D coverage of GLP-1 medications for non-weight-loss FDA-approved indications. November 2024.
2. Social Security Act, Section 1860D-2(e)(2). Part D excluded drugs.
3. U.S. Food and Drug Administration. Wegovy prescribing information including the cardiovascular indication.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM. 2023;389:2221-2232.
5. Inflation Reduction Act of 2022. Part D out-of-pocket cap and price negotiation provisions.
6. CMS Medicare Prescription Payment Plan guidance. 2025.
7. Social Security Administration. Extra Help (Low-Income Subsidy). 2026.
8. Congressional Budget Office. Estimates of removing the Part D weight-loss drug exclusion.
9. Treat and Reduce Obesity Act. Successive Congressional sessions.
10. Wilding JPH, et al. STEP 1. NEJM. 2021;384:989-1002.
11. American Heart Association and American College of Cardiology. Obesity and cardiovascular disease guidance.
12. Endocrine Society. Obesity pharmacotherapy clinical practice guideline.
13. Novo Nordisk. Patient Assistance Program application and eligibility.
14. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed clinicians through telehealth. We do not enroll beneficiaries in Medicare plans or adjudicate Medicare claims. Information here reflects publicly available materials as of May 2026 and is subject to change with future CMS rules or Congressional action.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy for an individual patient. It is not FDA-approved, is not equivalent to brand-name Wegovy, and is not billable to Medicare or any federal program. A prescribing clinician should be involved in the decision.

Results Disclaimer. Coverage, cost-sharing, and clinical outcomes vary based on plan, individual circumstances, and clinical response. The figures and criteria here are general and do not predict any specific case.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare is a federal program administered by CMS. FormBlends is independent.